The aims of this study were to explore whether BTK can serve as a therapeutic target in BA and MC and whether the BTK blockers currently used in clinical trials are able to suppress allergen‐induced (IgER‐dependent) activation and histamine release. The gene discussed is BTK; the disease is breast angiosarcoma.